Literature DB >> 24737346

A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.

Xiaoting Wang1, Youdong Lin, Fenghua Lan, Yinghao Yu, Xuenong Ouyang, Xuzhou Wang, Qiaojia Huang, Lie Wang, Jianming Tan, Feng Zheng.   

Abstract

PURPOSE: v-akt Murine thymoma viral oncogene homolog (AKT) pathway is critically involved in cancer cell growth, invasion, and survival. We examined the correlation between the genetic variations in molecules of AKT pathway and clinical outcomes of gastric cancer. PATIENTS AND METHODS: Six single nucleotide polymorphisms (SNPs) located in the four core genes of AKT pathway, namely the PIK3CA, PTEN, AKT1, and mTOR, were determined in 221 patients with stage T2 and T3 gastric cancer. Additionally, the activation of AKT1 in gastric cancer tissues was examined by immunostaining. The correlation between SNPs, AKT activation, and the progress of gastric cancer was analyzed after an average of 51-month follow-up.
RESULTS: The overall recurrence and survival rate in this study group were 54.8 and 46.6 %, respectively. The recurrence rate was reduced 30.4 %, and the survival rate was increased 33.7 % in patients with GG allele of a 3'-side AKT1 SNP (rs2498804). Significantly, GG allele was associated with lower AKT1 activation in gastric cancer tissues. On the contrary, CC allele of PTEN (rs701848) was associated with the increased risk of recurrence (hazard ratio [HR] 2.06, 95 % CI 1.19-3.58) and patient death (HR 2.01, 95 % CI 1.15-3.53).
CONCLUSIONS: The genetic variants in the PI3K/PTEN/AKT especially the GG allele in 3' side of AKT1 are closely related to clinical outcomes of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24737346     DOI: 10.1007/s00432-014-1663-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Authors:  Meng Chen; Jian Gu; George L Delclos; Ann M Killary; Zhen Fan; Michelle A T Hildebrandt; Robert M Chamberlain; H Barton Grossman; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 3.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 4.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 5.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

6.  Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression.

Authors:  Melanie Spears; Carrie A Cunningham; Karen J Taylor; Elizabeth A Mallon; Jeremy St J Thomas; Gillian R Kerr; Wilma J L Jack; Ian H Kunkler; David A Cameron; Udi Chetty; John M S Bartlett
Journal:  J Pathol       Date:  2012-04-30       Impact factor: 7.996

7.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Authors:  Eiji Oki; Hideo Baba; Eriko Tokunaga; Toshihiko Nakamura; Naoyuki Ueda; Motonori Futatsugi; Kohjiro Mashino; Manabu Yamamoto; Masahiko Ikebe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

8.  Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma.

Authors:  Angela B Y Hui; Alice Lin; Wei Xu; Levi Waldron; Bayardo Perez-Ordonez; Ilan Weinreb; Wei Shi; Jeff Bruce; Shao Hui Huang; Brian O'Sullivan; John Waldron; Patrick Gullane; Jonathan C Irish; Kelvin Chan; Fei-Fei Liu
Journal:  Clin Cancer Res       Date:  2013-03-04       Impact factor: 12.531

Review 9.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

10.  Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

Authors:  Do-Sun Byun; Kyucheol Cho; Byung-Kyu Ryu; Min-Goo Lee; Jae-Il Park; Kwon-Seok Chae; Hyo-Jong Kim; Sung-Gil Chi
Journal:  Int J Cancer       Date:  2003-04-10       Impact factor: 7.396

View more
  15 in total

1.  PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.

Authors:  Yang Yang; Wen Xu; Di Liu; Xi Ding; Bo Su; Yifeng Sun; Wen Gao
Journal:  Tumour Biol       Date:  2015-12-22

2.  BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy.

Authors:  Xiaoting Wang; Youdong Lin; Fenghua Lan; Yinghao Yu; Xuenong Ouyang; Wei Liu; Feilai Xie; Xuzhou Wang; Qiaojia Huang
Journal:  Med Oncol       Date:  2014-09-30       Impact factor: 3.064

3.  Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma.

Authors:  Liqiang Ma; Xiaoting Wang; Fenghua Lan; Yinghao Yu; Xuenong Ouyang; Wei Liu; Feilai Xie; Qiaojia Huang
Journal:  Med Oncol       Date:  2014-12-02       Impact factor: 3.064

4.  Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma.

Authors:  Youdong Lin; Xiaoting Wang; Yinghao Yu; Wei Liu; Feilai Xie; Xuenong Ouyang; Qiaojia Huang
Journal:  Oncol Lett       Date:  2017-09-29       Impact factor: 2.967

5.  Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.

Authors:  Lin Lin; Zhaoxu Zhang; Wen Zhang; Lin Wang; Jinwan Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Association of MTOR and AKT Gene Polymorphisms with Susceptibility and Survival of Gastric Cancer.

Authors:  Ying Piao; Ying Li; Qian Xu; Jing-wei Liu; Cheng-zhong Xing; Xiao-dong Xie; Yuan Yuan
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.

Authors:  Qiaojuan Guo; Tianzhu Lu; Yan Chen; Ying Su; Yuhong Zheng; Zeng Chen; Chao Chen; Shaojun Lin; Jianji Pan; Xianglin Yuan
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

8.  Association of Inflammation-Related Gene Polymorphisms With Susceptibility and Radiotherapy Sensitivity in Head and Neck Squamous Cell Carcinoma Patients in Northeast China.

Authors:  Ying Li; Li Zhu; Hongmin Yao; Ye Zhang; Xiangyu Kong; Liping Chen; Yingqiu Song; Anna Mu; Xia Li
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

Review 9.  Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects.

Authors:  Simona Granata; Alessandra Dalla Gassa; Amedeo Carraro; Matteo Brunelli; Giovanni Stallone; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2016-05-14       Impact factor: 5.923

10.  A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population.

Authors:  Meng-Yun Wang; Jing He; Mei-Ling Zhu; Xiao-Yan Teng; Qiao-Xin Li; Meng-Hong Sun; Xiao-Feng Wang; Ya-Jun Yang; Jiu-Cun Wang; Li Jin; Ya-Nong Wang; Qing-Yi Wei
Journal:  Sci Rep       Date:  2016-01-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.